Trial description:
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Contact name:
Dr Danish Mazhar
Trial start date:
Tuesday, October 8, 2019
Trial end date:
Tuesday, April 30, 2024
Trial tumour type:
Prostate
Show on Radiotherapy:
No
